Page 50 - EndoProxy2012_final

endo | 100 Endo Boulevard | Chadds Ford, Pennsylvania 19317 44
*The percentage of the class to be owned by such security holder represents less than 1%.
(a) “Beneficial ownership” is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes
more than the typical form of stock ownership, that is, stock held in the person’s name. The term also includes
what is referred to as “indirect ownership,” meaning ownership of shares as to which a person has or shares invest-
ment power. For purposes of this table, a person or group of persons is deemed to have “beneficial ownership” of
any shares as of a given date that such person has the right to acquire within 60 days after such date.
(b) Mr. Kimmel is the Chairman of the Board of Endo. The business address for Mr. Kimmel is c/o Rothschild, Inc., 1251
Avenue of the Americas, New York, New York 10022. Mr. Kimmel’s beneficial ownership represents (i) options to
purchase 43,167 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2000, 2004 and
2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 165,000 shares of common
stock held in trusts for which Mr. Kimmel serves as trustee and as to which shares Mr. Kimmel holds either the
sole or the shared power of disposition and power to vote. His beneficial ownership excludes (i) 2,500 shares of
common stock held in trusts for the benefit of one of Mr. Kimmel’s adult children, as to which shares Mr. Kimmel
has neither the power of disposition nor the power to vote, (ii) options to purchase 6,642 shares of common stock
granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be ex-
ercisable within the next 60 days and (iii) 5,481 shares of unvested restricted stock units.
(c) Mr. Delucca is a director of our company. The business address for Mr. Delucca is 314 Ardmore Road, Ho-Ho-Kus,
NJ 07423. Mr. Delucca’s beneficial ownership represents (i) options to purchase 33,167 shares of common stock
granted under the Endo Pharmaceuticals Holdings Inc. 2000, 2004 and 2007 Stock Incentive Plans which will be
exercisable within the next 60 days and (ii) 13,853 directly owned shares of common stock. His beneficial owner-
ship excludes (i) options to purchase 6,642 shares of common stock granted under the Endo Pharmaceuticals
Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii)
5,481 shares of unvested restricted stock units.
(d) Dr. Hutson is a director of Endo. Dr. Hutson’s beneficial ownership represents (i) options to purchase 11,617 shares
of our common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 Stock Incentive Plan which will
be exercisable within the next 60 days and (ii) 14,002 directly owned shares of common stock. Her beneficial own-
ership excludes (i) options to purchase 6,568 shares of common stock granted under the Endo Pharmaceuticals
Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii)
5,481 shares of unvested restricted stock units.
(e) Mr. Hyatt is a director of Endo. The business address for Mr. Hyatt is c/o Irving Place Capital, 227 Park Avenue,
New York, New York 10172. Mr. Hyatt’s beneficial ownership represents (i) options to purchase 58,167 shares of
common stock granted under the Endo Pharmaceuticals Holdings Inc. 2000, 2004 and 2007 Stock Incentive Plans
which will be exercisable within the next 60 days, (ii) 228,853 directly owned shares of common stock and (iii)
20,750 shares held in trusts for which Mr. Hyatt serves as trustee and as to which shares Mr. Hyatt holds either
Name of Beneficial Owner
Number of
Shares of
Common Stock
Beneficially
Owned (a)
Percentage of
Class (a)
Directors and Executive Officers:
Roger H. Kimmel (b) 208,167 *
John J. Delucca (c) 47,020 *
Nancy J. Hutson, Ph.D. (d)(o) 25,619 *
Michael Hyatt (e) 307,770 *
William P. Montague (f) 27,233 *
David B. Nash, M.D., M.B.A. (g) - *
Joseph C. Scodari (h)(o) 39,044 *
William F. Spengler (i) 38,670 *
David P. Holveck (j)(o) 639,702 *
Alan G. Levin (k)(o) 92,178 *
Julie McHugh (l)(o) 72,422 *
Ivan P. Gergel, M.D. (m)(o) 69,233 *
Caroline B. Manogue (n)(o) 419,504 *
All current directors and executive officers of Endo Pharmaceuticals Holdings Inc. as a group (13 persons) 1,986,562 1.7%
Other Stockholders:
Capital Research Global Investors (p) 10,600,758 9.1%
Janus Capital Management (q) 8,585,257 7.3%
BlackRock Institutional Trust Company, N.A. (r) 6,773,380 5.8%
Fidelity Management & Research (s) 6,082,831 5.2%
LSV Asset Management (t) 5,859,873 5.0%